Phaseline

Companies › Proniras

Proniras: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tezampanel
Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist
GRIA4, GRIA3, GRIA2, GRIA1, GRIK1Phase 1Opioid Use DisorderOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06538558TezampanelPhase 1Opioid Use DisorderPsychiatryOct 2027

Targets

GRIA4 (1) GRIA3 (1) GRIA2 (1) GRIA1 (1) GRIK1 (1)

Companies with the same targets

Neurocrine Biosciences Eisai Upsher-Smith Laboratories

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.